IL17A and cancer: Undoubtedly, therefore, involvement of certain interleukins including IL-6, IL-4, IL-17A and IL-32β in certain EMT pathways signifies their specific contribution to metastatic processes, thereby warranting further work into the development of diagnostic and immunotherapeutic tools in cancer.